[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634909":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":25,"locations":31,"responsibleParty":76,"collaborators":24,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":24,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":24,"enrollmentInfo":87,"targetDuration":24,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":24,"overallStatus":34,"whyStopped":24,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},{"fullName":5,"class":6},"Janux Therapeutics","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Escalation","EXPERIMENTAL","JANX014 will be administered at increasing dose levels per cohort to determine the maximum tolerated dose.",[13],"Biological: JANX014",{"label":15,"type":10,"description":16,"interventionNames":17},"Dose Expansion","Participants will be dosed at levels previously declared tolerable.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"BIOLOGICAL","JANX014","JANX014 will be administered via IV dosing",[9,15],null,[26],{"name":27,"role":28,"phone":29,"phoneExt":24,"email":30},"Janux Therapeutics, MD","CONTACT","+1 858-206-8471","PRCA-014-001_ct.gov@januxrx.com",[32,46,56,66],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":24},"Washington University School of Medicine","RECRUITING","St Louis","Missouri","63108","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-90.19789,38.62727,{"lat":44,"lon":43},{"facility":47,"status":34,"city":48,"state":49,"zip":50,"country":38,"countryCode":39,"cosmosGeoPoint":51,"geoPoint":55,"contacts":24},"Prisma Health Cancer Institute","Greenville","South Carolina","29605",{"type":41,"coordinates":52},[53,54],-82.39401,34.85262,{"lat":54,"lon":53},{"facility":57,"status":34,"city":58,"state":59,"zip":60,"country":38,"countryCode":39,"cosmosGeoPoint":61,"geoPoint":65,"contacts":24},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":41,"coordinates":62},[63,64],-86.78444,36.16589,{"lat":64,"lon":63},{"facility":67,"status":34,"city":68,"state":69,"zip":70,"country":38,"countryCode":39,"cosmosGeoPoint":71,"geoPoint":75,"contacts":24},"SCRI at Mary Crowley","Dallas","Texas","75230",{"type":41,"coordinates":72},[73,74],-96.80667,32.78306,{"lat":74,"lon":73},{"type":77,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100634909","study-of-janx014-in-subjects-with-metastatic-castration-resistant-prostate-cancer-100634909",false,"NCT07545811","Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer","A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants With Prostate Cancer","Inclusion Criteria:\n\n* Male ≥18 years of age at the time of signing informed consent\n* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* For Dose Escalation: Having mCRPC that progressed after at least one novel anti-androgen therapy and at least one taxane containing regimen. Participants who have actively refused a taxane containing regimen or are medically unsuitable to receive taxane are eligible.\n* Adequate organ function\n* For Dose Expansion Part: Have received ≤ 2 anti-androgen therapies in either the HSPC or CRPC setting and no more than 1 prior taxane regimen in the HSPC setting. Participants who have actively refused a taxane regimen or are medically unsuitable to receive taxane are eligible.\n\nExclusion Criteria:\n\n* Prior solid organ transplant\n* Prior treatment with any CAR-T cell therapy, approved or investigational T-cell engager therapy, and prior receipt of radioligand therapy\n* Clinically significant cardiovascular disease","MALE","18 Years",{"count":88,"type":89},43,"ESTIMATED","INTERVENTIONAL",[92],"PHASE1","This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).",[95,96,97],"Prostate Cancer","Metastatic Castration-resistant Prostate Cancer","Castration-resistant Prostate Cancer","2026-08-06",{"date":100,"type":101},"2026-08-10","ACTUAL",{"date":103,"type":101},"2026-04-15",{"date":105,"type":89},"2029-03",{"name":5,"class":6},4]